Japan is once again tightening its stance on cannabis-derived compounds. This time, the focus is on cannabinol (CBN), a cannabinoid less well-known than THC or CBD, but one that is increasingly found in products aimed at relaxation and sleep support. The decision, reported by International CBC, marks a new chapter in the Asian country’s regulation, which has been combining limited medical access with strict punitive policies.
What Is CBN—and Why Was It Gaining Popularity?
To understand the measure, we must first look at the context. Cannabis contains dozens of cannabinoids: the best-known are THC and CBD, but in recent years the market has begun exploring “secondary” compounds such as CBN, which is primarily associated with sleep aids.
In Japan, where THC remains strictly prohibited, these derivatives fell into a legal gray area. Since they were not explicitly regulated, they started being sold in various formats, such as edibles, oils, tinctures, vaep products, and functional snacks.
This growth was no accident. Globally, “non-traditional” cannabinoids have been gaining ground as alternatives in restricted markets, taking advantage of legal loopholes.
The Japanese Government’s Decision: Total Ban on CBN
That loophole has just been closed. Japan’s Ministry of Health has classified CBN as a “designated drug,” effectively banning it almost entirely.
As reported by The Japan Times, Japan’s Ministry of Health announced on Wednesday that it has classified cannabinol as a “controlled substance,” banning its production, import, sale, and consumption as of June 1, except for limited medical purposes. This means that, as of that date, all commercial and consumer activity involving CBN will be prohibited, with very limited exceptions.
The measure directly impacts a market that had grown significantly in both brick-and-mortar and online stores. As the same publication details: “Under the revised ordinance, CBN products—which are sold …
Read More
Author: Camila Berriex / High Times
